Evolution of the human CNS cholineric system: Has this resulted in the emergence of psychiatric disease?

Australian and New Zealand Journal of Psychiatry

Volumn 43, Issue 11, 2009, Pages 1016-1028

  Dean, Brian ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Acetylcholine cholinergic receptors; Darwin; Evolution; Schizophrenia

Indexed keywords

ACETYLCHOLINE; CHOLINE;

CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; GENE LOCATION; HUMAN; MENTAL DISEASE; MOLECULAR EVOLUTION; NEUROTRANSMISSION; PROTEIN FUNCTION; REVIEW;

ACETYLCHOLINE; CENTRAL NERVOUS SYSTEM; EVOLUTION; HUMANS; MENTAL DISORDERS; NEURONS; RECEPTORS, CHOLINERGIC; SYNAPTIC TRANSMISSION;

EID: 70449353719     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670903270431     Document Type: Review

References (116)

1. Darwin C. On the origins of species by means of natural selection, or the preservation of favoured races in the struggle for life. London : John Murray , 1859.
2. Dawkins R. The selfish gene. Oxford: Oxford University Press, 1976.
3. Lamarck J-B. Philosophie zoologique, ou exposition des considérations relatives à l'histoire naturelle des animaux, a 'la diversite' de leur organisation et des faculte's qu'ils en obtiennent. Paris: Dentu, 1809.
4. van Vliet J, Oates NA, Whitelaw E. Epigenetic mechanisms in the context of complex diseases. Cell Mol Life Sci 2007; 64: 1531-1538.
5. Youngson NA, Whitelaw E. Transgenerational epigenetic effects. Annu Rev Genomics Hum Genet 2008; 9: 233-257.
6. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry 2000; 47: 210-220.
7. Crow TJ. Auditory hallucinations as primary disorders of syntax: an evolutionary theory of the origins of language. Cognit Neuropsychiatry 2004; 9: 125-145.
8. Dean B. Is schizophrenia the price of human central nervous system complexity? Aust N Z J Psychiatry 2009; 43: 13-24.
9. Dean B. Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue. Postgrad Med J 2002; 78: 142-148.
10. Dean B. Changes in the molecular structure of the brain in bipolar disorder: findings using human postmortem brain tissue. World J Biol Psychiatry 2002; 3: 125-132.
11. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998; 59 (Suppl 14) : 11-14.
12. Michelson MJ. Some aspects of evolutionary pharmacology. Biochem Pharmacol 1974; 23: 2211-2224.
13. Dale HH. The action of certain esters and ethers of choline, and their relation to muscarine. J Pharmacol Exp Ther 1914; 6: 147-190.
14. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007; 12: 232-246.
15. Gibbons AS, Scarr E, McLean C, Sundram S, Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 2008.
16. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neuro transmitter correlate of consciousness? Trends Neurosci 1999; 22: 273-280.
17. Taylor P, Brown JH. Acetycholine. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, eds Basic neurochemistry. New York: Lippincott-Raven, 1999; 213-242.
18. Felder CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 1995; 9: 619-625.
19. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009; 89: 73-120.
20. McNeil SD, Nuccio ML, Ziemak MJ, Hanson AD. Enhanced synthesis of choline and glycine betaine in transgenic tobacco plants that overexpress phosphoethanolamine N-methyltransferase. Proc Natl Acad Sci USA 2001; 98: 10001-10005.
21. Zeisel SH. Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr 1981; 1: 95-121.
22. Kent C. Eukaryotic phospholipid biosynthesis. A nnu Rev Biochem 1995; 64: 315-343.
23. Goldfine H, Hagen P. N-methyl groups in bacterial lipids. 3. Phospholipids of hyphomicrobia. J Bacteriol 1968; 95: 367-375.
24. Snipes W, Keith A, Wanda P. Active transport of choline by a marine pseudomonad. J Bacteriol 1974; 120: 197-202.
25. Yamamura HI, Snyder SH. Choline: high-affi nity uptake by rat brain synaptosomes. Science 1972; 178: 626-628.
26. Gilboa-Garber N, Zakut V, Mizrahi L. Production of cholinesterase by Pseudomonas aeruginosa, its regulation by glucose and cyclic AMP and inhibition by antiserum. Biochim Biophys Acta 1973; 297: 120-124.
27. Fitch WW. Studies on a cholinesterase of Pseudomonas Fluorescens. I. Enzyme induction and the metabolism of acetylcholine. Biochemistry 1963; 2: 1217-1221.
28. Salvano MA, Lisa TA, Domenech CE. Choline transport in Pseudo monas aeruginosa. Mol Cell Biochem 1989; 85: 81-89.
29. Ferguson SM, Blakely RD. The choline transporter resurfaces: new roles for synaptic vesicles? Mol Interv 2004; 4: 22-37.
30. Raiteri M, Marchi M, Caviglia AM. Studies on a possible functional coupling between presynaptic acetylcholinesterase and high-affi nity choline uptake in the rat brain. J Neurochem 1986; 47: 1696-1699.
31. Ferguson SM, Savchenko V, Apparsundaram S et al. Vesicular localization and activity-dependent traffi cking of presynaptic choline transporters. J Neurosci 2003; 23: 9697-9709.
32. Pocard JA, Bernard T, Smith LT, Le RD. Characterization of three choline transport activities in Rhizobium meliloti: modulation by choline and osmotic stress. J Bacteriol 1989; 171: 531-537.
33. Okuda T, Haga T, Kanai Y, Endou H, Ishihara T, Katsura I. Identification and characterization of the high-affi nity choline transporter. Nat Neurosci 2000; 3: 120-125. (Pubitemid 30126326)
34. Hedges SB. The origin and evolution of model organisms. Nat Rev Genet 2002; 3: 838-849.
35. Sastry BV, Sadavongvivad C. Cholinergic systems in nonnervous tissues. Pharmacol Rev 1978; 30: 65-132.
36. Kawashima K, Misawa H, Moriwaki Y et al. Ubiquitous expression of acetylcholine and its biological functions in life forms without nervous systems. Life Sci 2007; 80: 2206-2209.
37. Horiuchi Y, Kimura R, Kato N et al. Evolutional study on acetylcholine expression. Life Sci 2003; 72: 1745-1756.
38. Chet I, Henis Y, Mitchell R. Effect of biogenic amines and cannabinoids on bacterial chemotaxis. J Bacteriol 1973; 115: 1215-1218.
39. Hartmann E, Kilbinger H. Occurrence of light-dependent acetylcholine concentrations in higher plants. Experientia 1974; 30: 1397-1398.
40. Wessler I, Kilbinger H, Bittinger F, Kirkpatrick CJ. The bio - logical role of non-neuronal acetylcholine in plants and humans. Jpn J Pharmacol 2001; 85: 2-10.
41. Odjakova M, Hadjiivanova C. Animal neurotransmitter substances in plants. Bulg J Plant Physiol 1997; 23: 94-102.
42. Reimer RJ, Fon EA, Edwards RH. Vesicular neurotransmitter transport and the presynaptic regulation of quantal size. Curr Opin Neurobiol 1998; 8: 405-412.
43. Smith CD, Shu S, Mungall CJ, Karpen GH. The Release 5.1 annotation of Drosophila melanogaster heterochromatin. Science 2007; 316: 1586-1591.
44. Takamura K, Egawa T, Ohnishi S, Okada T, Fukuoka T. Developmental expression of ascidian neurotransmitter synthesis genes. I. Choline acetyltransferase and acetylcholine transporter genes. Dev Genes Evol 2002; 212: 50-53.
45. Nierman WC, Pain A, Anderson MJ et al. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 2005; 438: 1151-1156.
46. Prado MA, Reis RA, Prado VF, de Mello MC, Gomez MV, de Mello FG. Regulation of acetylcholine synthesis and storage. Neurochem Int 2002; 41: 291-299.
47. Cervini R, Houhou L, Pradat PF, Bejanin S, Mallet J, Berrard S. Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. J Biol Chem 1995; 270: 24654-24657.
48. Cervini R, Rocchi M, DiDonato S, Finocchiaro G. Isolation and sub-chromosomal localization of a DNA fragment of the human choline acetyltransferase gene. Neurosci Lett 1991; 132: 191-194.
49. Erickson JD, Varoqui H, Schafer MK et al. Functional identification of a vesicular acetylcholine transporter and its expression from a 'cholinergic' gene locus. J Biol Chem 1994; 269: 21 929- 21 932.
50. Welsch F. Uptake of acetylcholine by human placenta fragments and slices from guinea pig and rat placenta. Biochem Pharmacol 1976; 25: 81-89.
51. Rama Sastry BV, Olubadewo J, Harbison RD, Schmidt DE. Human placental cholinergic system. Occurrence, distribution and variation with gestational age of acetylcholine in human placenta. Biochem Pharmacol 1976; 25: 425-431.
52. Li WH, Gojobori T. Rapid evolution of goat and sheep globin genes following gene duplication. Mol Biol Evol 1983; 1: 94-108.
53. Hughes AL, Ota T, Nei M. Positive Darwinian selection promotes charge profi le diversity in the antigen-binding cleft of class I major- histocompatibility-complex molecules. Mol Biol Evol 1990; 7: 515-524.
54. Hanada K, Shiu SH, Li WH. The nonsynonymous/synonymous substitution rate ratio versus the radical/conservative replacement rate ratio in the evolution of mammalian genes. Mol Biol Evol 2007; 24: 2235-2241.
55. Jin Z. Muscarine, imidazole, oxazole and thiazole alkaloids. Nat Prod Rep 2009; 26: 382-445.
56. Wang SS, Shi QM, Li WQ, Niu JF, Li CJ, Zhang FS. Nicotine concentration in leaves of fl ue-cured tobacco plants as affected by removal of the shoot apex and lateral buds. J Integr Plant Biol 2008; 50: 958-964.
57. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 1996; 10: 69-99.
58. Venter JC, di Porzio U, Robinson DA et al. Evolution of neurotrans mitter receptor systems. Prog Neurobiol 1988; 30: 105-169.
59. Mongin E, Louis C, Holt RA, Birney E, Collins FH. The Anopheles gambiae genome: an update. Trends Parasitol 2004; 20: 49-52.
60. Hwang JM, Chang DJ, Kim US et al. Cloning and functional characterization of a Caenorhabditis elegans muscarinic acetylcholine receptor. Receptors Channels 1999; 6: 415-424.
61. Bencan Z, Levin ED. The role of alpha7 and alpha4beta2 nicotinic receptors in the nicotine-induced anxiolytic effect in zebrafish. Physiol Behav 2008; 95: 408-412.
62. Heil JE, Oland LA, Lohr C. Acetylcholine-mediated axonglia signaling in the developing insect olfactory system. Eur J Neurosci 2007; 26: 1227-1241.
63. Braun G, Bicker G. Habituation of an appetitive reflex in the honeybee. J Neurophysiol 1992; 67: 588-598.
64. Ismail N, Robinson GE, Fahrbach SE. Stimulation of muscarinic receptors mimics experience-dependent plasticity in the honey bee brain. Proc Natl Acad Sci USA 2006; 103: 207-211.
65. Thiel CM. Cholinergic modulation of learning and memory in the human brain as detected with functional neuroimaging. Neurobiol Learn Mem 2003; 80: 234-244.
66. Bowie CR, Harvey PD. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am 2005; 28: 613-633, 626.
67. Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK. Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 2006; 60: 93-105.
68. Sachs-Ericsson N, Joiner T, Blazer DG. The influence of lifetime depression on self-reported memory and cognitive problems: results from the National Comorbidity Survey-Replication. Aging Ment Health 2008; 12: 183-192.
69. Geyer MA, Braff DL. Habituation of the Blink reflex in normals and schizophrenic patients. Psychophysiology 1982; 19: 1-6.
70. Carroll CA, Vohs JL, O'Donnell BF, Shekhar A, Hetrick WP. Sensorimotor gating in manic and mixed episode bipolar disorder. Bipolar Disord 2007; 9: 221-229.
71. Ostermann J, Soros P, Schwindt W, Pfleiderer B. Altered habituation in the auditory cortex in a subgroup of depressed patients by functional magnetic resonance imaging. Neuropsy chobiology 2004; 49: 5-9.
72. Yokoyama S, Isenberg KE, Wright AF. Adaptive evolution of G-protein coupled receptor genes. Mol Biol Evol 1989; 6: 342-353.
73. Ortells MO, Lunt GG. Evolutionary history of the ligand-gated ion-channel superfamily of receptors. Trends Neurosci 1995; 18: 121-127.
74. Tsunoyama K, Gojobori T. Evolution of nicotinic acetylcholine receptor subunits. Mol Biol Evol 1998; 15: 518-527.
75. Le Novere N, Changeux JP. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol 1995; 40: 155-172.
76. Dorus S, Vallender EJ, Evans PD et al. Accelerated evolution of nervous system genes in the origin of Homo sapiens. Cell 2004; 119: 1027-1040.
77. Shirvan MH, Pollard HB, Heldman E. Mixed nicotinic and muscarinic features of cholinergic receptor coupled to secretion in bovine chromaffin cells. Proc Natl Acad Sci USA 1991; 88: 4860-4864.
78. Grando SA. Biological functions of keratinocyte cholinergic receptors. J Invest Dermatol Symp Proc 1997; 2: 41-48.
79. Kong WJ, Cheng HM, van CP. Expression of nicotinic acetylcholine receptor subunit alpha9 in type II vestibular hair cells of rats. Acta Pharmacol Sin 2006; 27: 1509-1514.
80. Taranda J, Maison SF, Ballestero JA et al. A point mutation in the hair cell nicotinic cholinergic receptor prolongs cochlear inhibition and enhances noise protection. PloS Biol 2009; 7: e18.
81. McEvoy JP, Allen TB. The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome. Curr Drug Targets CNS Neurol Disord 2002; 1: 433-442.
82. McGeer PL, McGeer EG. Possible changes in striatal and limbic cholinergic systems in schizophrenia. Arch Gen Psychiatry 1977; 34: 1319-1323.
83. Haroutunian V, Davidson M, Kanof PD et al. Cortical cholinergic markers in schizophrenia. Schizophr Res 1994; 12: 137-144.
84. Karson CN, Casanova MF, Kleinman JE, Griffi n WS. Choline acetyltransferase in schizophrenia. Am J Psychiatry 1993; 150: 454-459.
85. Holt DJ, Herman MM, Hyde TM et al. Evidence for a defi cit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 1999; 94: 21-31.
86. Watanabe S, Nishikawa T, Takashima M, Toru M. Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 1983; 33: 2187-2196.
87. Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1996; 1: 54-58.
88. Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem 2008; 107: 1188-1195.
89. Dean B, Crook JM, Pavey G, Opeskin K, Copolov DL. Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia. Mol Psychiatry 2000; 5: 203-207.
90. Crook JM, Dean B, Pavey G, Copolov D. The binding of [3H] AF-DX 384 is reduced in the caudate-putamen of subjects with schizo phrenia. Life Sci 1999; 64: 1761-1771.
91. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 2000; 48: 381-388.
92. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158: 918-925.
93. Zavitsanou K, Katsifi s A, Mattner F, Huang XF. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004; 29: 619-625.
94. Deng C, Huang XF. Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia. J Neurosci Res 2005; 81: 883-890.
95. Newell KA, Zavitsanou K, Jew SK, Huang XF. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 225-233.
96. Dean B, Gray L, Keriakous D, Scarr E. A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus Relat Syst 2004; 2: 287-295.
97. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002; 7: 1083-1091.
98. Mancama D, Arranz MJ, Landau S, Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 119B: 2-6.
99. Scarr E, Keriakous D, Crossland N, Dean B. No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia. Life Sci 2006; 78: 1231-1237.
100. Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry 2007; 61: 1161-1170.
101. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995; 38: 22-33.
102. Court J, Spurden D, Lloyd S et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alphabungarotoxin and nicotine binding in the thalamus. J Neurochem 1999; 73: 1590-1597.
103. Marutle A, Zhang X, Court J et al. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 2001; 22: 115-126.
104. Martin-Ruiz CM, Haroutunian VH, Long P et al. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizo phrenia. Biol Psychiatry 2003; 54: 1222-1233.
105. Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000; 74: 237-243.
106. De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. Acta Psychiatr Scand 2006; 114: 211-215.
107. Durany N, Zochling R, Boissl KW et al. Human postmortem striatal a4b2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 2000; 287: 109-112.
108. Court JA, Piggott MA, Lloyd S et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 2000; 98: 79-87.
109. Breese CR, Lee MJ, Adams CE et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000; 23: 351-364.
110. Mousavi M, Hellstrom-Lindahl E, Guan ZZ, Shan KR, Ravid R, Nordberg A. Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease. Neuroscience 2003; 122: 515-520.
111. Leonard S, Breese C, Adams C et al. Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur J Pharmacol 2000; 393: 237-242.
112. Meltzer HY, Moline R. Muscle abnormalities in acute psychoses. Arch Gen Psychiatry 1970; 23: 481-491.
113. Jeffares DC, Penkett CJ, Bahler J. Rapidly regulated genes are intron poor. Trends Genet 2008; 24: 375-378.
114. Chapman CG, Browne MJ. Isolation of the human ml (Hml) muscarinic acetylcholine receptor gene by PCR amplification. Nucleic Acids Res 1990; 18: 2191.
115. McOmish CE, Burrows E, Howard M et al. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. Mol Psychiatry 2008; 13: 661-672.
116. Burmeister M, McInnis MG, Zollner S. Psychiatric genetics: progress amid controversy. Nat Rev Genet 2008; 9: 527-540